SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-005075
Filing Date
2022-01-10
Accepted
2022-01-10 07:37:03
Documents
15
Period of Report
2022-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d269867d8k.htm   iXBRL 8-K 26320
2 EX-99.1 d269867dex991.htm EX-99.1 36538
6 GRAPHIC g269867dsp001.jpg GRAPHIC 6487
7 GRAPHIC g269867dsp01.jpg GRAPHIC 1573
  Complete submission text file 0001193125-22-005075.txt   203521

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20220110.xsd EX-101.SCH 2894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20220110_lab.xml EX-101.LAB 17373
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20220110_pre.xml EX-101.PRE 10954
9 EXTRACTED XBRL INSTANCE DOCUMENT d269867d8k_htm.xml XML 3461
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 22519708
SIC: 2834 Pharmaceutical Preparations